Amgen Will Launch Palifermin In Late January Under Brand Name Kepivance

The oral mucositis treatment clears FDA under priority review. Labeling includes the precaution that "Kepivance has been shown to enhance the growth of human epithelial tumor cell lines in vitro." Palifermin's safety and efficacy were assessed in two studies examining 381 patients.